Navigation Links
NovaBay Pharmaceuticals, Inc. Reports Second Quarter 2009 Financial Results
Date:8/14/2009

ons. The company has a licensing and research collaboration agreement with Alcon, Inc. for use of its Aganocides in the eye, ear and sinus, and in contact lens solutions. NovaBay has entered into an agreement with Galderma S.A. to develop and commercialize Aganocides in acne, impetigo and other dermatological indications. NovaBay((R)) and Aganocide((R)) are trademarks of NovaBay Pharmaceuticals, Inc. For more information on NovaBay, visit www.novabaypharma.com.




                         NOVABAY PHARMACEUTICALS, INC
                    (formerly NovaCal Pharmaceuticals Inc.)
                        (a developmental stage company)

                         CONSOLIDATED BALANCE SHEETS
                    (in thousands, except per share data)

                                                      December 31,   June 30,
                                                           2008        2009
                                                                   (unaudited)
    ASSETS
      Current assets:
        Cash and cash equivalents                       $12,099       $8,000
        Short-term investments                                         2,685
        Prepaid expenses and other current assets           414          769
        Total current assets                             12,513       11,454
      Property and equipment, net                         1,456        1,575
      TOTAL ASSETS                                      $13,969      $13,029


    LIABILITIES AND STOCKHOLDERS' EQUITY
    Liabilities:
      Current liabilities:
        Accounts payable                                   $406         $533
        Accrued liabilities                               1,166          636
        Capital lease obligation                             42           29
        Equipment loan                                      366          387
        Deferred revenue                                  2,500     
'/>"/>
SOURCE  NovaBay Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 

Related biology technology :

1. NovaBay(R) Pharmaceuticals Names Roy J. Wu as Senior Vice President for Business Development
2. NovaBay(R) Pharmaceuticals to Present at Jesup & Lamont 2009 Growth Stock Conference
3. NovaBay Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
4. NovaBay and Galderma Enter Into Global Agreement to Develop and Commercialize NovaBays Novel Aganocide Drugs for Major Dermatological Conditions
5. NovaBay Pharmaceuticals Prices Initial Public Offering of Common Stock
6. Biostar Pharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
7. Biostar Pharmaceuticals, Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Friday, August 14, 2009 at 10:30 a.m. EDT
8. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
9. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
11. Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... NJ (PRWEB) May 24, 2013 Dr. Ingrid ... NJ and Swedesboro, NJ, are proud to announce an Open ... will take place on Saturday, June 8th from 10 AM ... Warmuth, Anamaria Newport, MHS, PA-C and staff will be on ... fillers, laser and aesthetic treatments, and provide complimentary cosmetic consultations. ...
(Date:5/24/2013)... Senomyx , Inc. (NASDAQ: ... to discover, develop, and commercialize novel flavor ingredients, announced ... the Company,s Vice President, Biology and Gwen ... Communications, will present an overview of Senomyx,s technology and ... Time (7:25 a.m. Pacific Time) during the Citi 2013 ...
(Date:5/24/2013)... 24, 2013 Vestiage, Inc. (stock ... focused on science-based research and development, sales and ... and nutraceuticals, announced today that it is awarding ... the sale of Reluma Skin Illuminating Facial Care. ... application by sending an email to info(at)vestiageinc(dot)com and ...
(Date:5/23/2013)... Colo. , May 23, 2013 Venaxis, ... diagnostic company focused on obtaining FDA clearance and commercializing ... today announced the pricing of an underwritten public offering ... warrants to purchase 3,500,000 shares of its common stock ... a combined public offering price of $1.25 per share ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Venaxis Announces Pricing of Offering of Common Stock and Warrants 2Venaxis Announces Pricing of Offering of Common Stock and Warrants 3
... markets, the trend in health care employment could be counted on ... bringing yearly growth up over 345,000.The MedZilla.com Employment Report analyzes the ... ... Seattle, WA (Vocus) December 3, 2008 -- The U.S. economy ...
... and HOUSTON, Dec. 2 Transgenomic,Inc. (OTC ... Inc. (OTC,Bulletin Board: PWRM) today announced that ... acquire exclusive rights for Power3 Medical,s Neurodegenerative,Biomarkers, ... Alzheimer,s,and Parkinson,s disease. Transgenomic plans to ...
... postmenopause , , MONTVALE, N.J., ... symptoms is a challenge for women experiencing menopause. OBG ... have recently published a supplement titled Vasomotor symptoms: Managing ... James McGregor, MD, CM and Lee P. Shulman, MD, discuss ...
Cached Biology Technology:The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: October 2008 Employment Outlook for Biotech/Pharma/Health 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 2Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 3Transgenomic Signs Letter of Intent for an Agreement to Exclusive License With Option to Acquire Power3 Medical Products' Neurodegenerative Diagnostics 4
(Date:5/24/2013)... noise in one French Quarter neighborhood of New Orleans ... ordinances, Annette Hurley, PhD, Assistant Professor of Audiology at ... a third-year LSUHSC doctor of audiology student, recommend that ... health. Their case study is published online in the ... ., "An important part of an audiologist,s practice is ...
(Date:5/23/2013)... honored more than 165 staff for their creation, ... annual Intellectual Property Commercialization Recognition & Rewards Program ... laboratory named materials scientist Jun Liu Inventor of ... that can store large amounts of energy, ease ... time it takes to charge cell phones, electric ...
(Date:5/23/2013)... the overall health, development, and academic success of ... ensuring that all students have opportunities to engage ... vigorous or moderate-intensity physical activity, says a new ... estimates suggest that only about half of school-age ... health and development. The report recommends that ...
Breaking Biology News(10 mins):Please do try this at home 2PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 2Schools should provide opportunities for 60 minutes of daily physical activity to all students 3
... German . , In emerging countries such as ... consumption of red meat has quadrupled since 1961. The United ... lead to a doubling of global meat production by the ... limited farmland resources, will still be able to meet all ...
... DECEMBER 30, 2010 A recent study by a team ... incident of pathogens in biosolids over a 19 year period ... researchers also analyzed pathogen levels in biosolids at 18 wastewater ... analysis indicates pathogens levels have dropped since the implementation of ...
... you know that when you pick up a product promoted ... significant amount of this potentially harmful substance? An article by ... published in the January/February 2011 issue of the American ... can result in medically significant intake of harmful trans fat, ...
Cached Biology News:Eating low-fat, thanks to lupin proteins 2Wastewater treatment lowers pathogen levels 2Call for truth in trans fats labeling by the FDA 2
Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Direct ELISA Assay Diluent, 10 L...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
Biology Products: